Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).

The Pan African medical journal - 1 Jan 2021

Kouamou Vinie, Ndhlovu Chiratidzo Ellen, Katzenstein David, Manasa Justen

Abstract excerpt

INTRODUCTION: pre-treatment drug resistance (PDR) can compromise the 3rd 95-95-95 global target for viral load suppression. The high complexity and cost of genotyping assays limits routine testing in many resource limited settings (RLS). We assessed the performance of a rapid HIV-1 drug resistance assay, the Pan Degenerate Amplification and Adaptation (PANDAA) assay when screening for significant HIV-1 drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genotype

Share to HIV Infections

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34795836
DOI: 10.11604/pamj.2021.40.57.28558
PMCID: PMC8571918

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).PMID 34795836Read ↗

Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.Semantic proximity Read ↗

Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in BotswanaSemantic proximity Read ↗

PANDAA-monium: Intentional violations of conventional qPCR design enables rapid, HIV-1 subtype-independent drug resistance SNP detectionSemantic proximity Read ↗

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017-2023.Semantic proximity Read ↗

PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.Semantic proximity Read ↗

The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated PatientsSemantic proximity Read ↗

HIV-1 Drug Resistance Detected by Next-Generation Sequencing among ART-Naïve Individuals: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance PipelineSemantic proximity Read ↗

Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017-2018 and 2020-2021 following a WHO Survey.Semantic proximity Read ↗

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.Semantic proximity Read ↗

Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.